



JAMAICA HOSPITAL MEDICAL CENTER

*Member of
MediSys Health Network, Inc.
and affiliated with
Flushing Hospital Medical Center*

8900 Van Wyck Expressway, Jamaica, NY 11418

Dear Manufacturers,

I am writing on behalf of Jamaica Hospital Medical Center (JHMC) to inform manufacturers that JHMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of JHMC's compliance with 340B Drug Pricing Program (340B Program) requirements. JHMC's 340B ID is DSH330014.

As background, JHMC qualified for the 340B Program as a disproportionate share hospital located in Jamaica, New York and has participated in the 340B Program since October 1, 2004.

Through the audit process, HRSA found JHMC to have non-compliance within its 340B Program and responsible for repayment as a result of the following findings:

1. JHMC dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B); and
2. 340B drugs were not properly accumulated. JHMC did not have adequate controls in place to ensure proper accumulated and prevention of diversion of 340B drugs, as prohibited by 42 USC 256b(a)(5)(B).

JHMC has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from JHMC and believe repayment may be owed for the findings described in this letter, or if you have any questions or comments regarding the findings described in this letter please contact Nicholas Pantaleo at 718-206-6053 or Qazi Halim at 516-810-0999.

Sincerely,

Mounir F. Doss
Executive Vice President and Chief Financial Officer
Jamaica Hospital Medical Center

You Can Count On Us For Life